Annual EBITDA
-$25.42 M
+$2.20 M+7.97%
December 31, 2023
Summary
- As of February 12, 2025, CYCC annual EBITDA is -$25.42 million, with the most recent change of +$2.20 million (+7.97%) on December 31, 2023.
- During the last 3 years, CYCC annual EBITDA has fallen by -$14.81 million (-139.47%).
- CYCC annual EBITDA is now -103.22% below its all-time high of $788.80 million, reached on January 1, 1994.
Performance
CYCC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$2.18 M
+$1.46 M+40.20%
September 30, 2024
Summary
- As of February 12, 2025, CYCC quarterly EBITDA is -$2.18 million, with the most recent change of +$1.46 million (+40.20%) on September 30, 2024.
- Over the past year, CYCC quarterly EBITDA has increased by +$3.18 million (+59.34%).
- CYCC quarterly EBITDA is now -3.42% below its all-time high of -$2.10 million, reached on September 30, 2017.
Performance
CYCC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$15.52 M
+$4.66 M+23.10%
September 30, 2024
Summary
- As of February 12, 2025, CYCC TTM EBITDA is -$15.52 million, with the most recent change of +$4.66 million (+23.10%) on September 30, 2024.
- Over the past year, CYCC TTM EBITDA has increased by +$9.90 million (+38.95%).
- CYCC TTM EBITDA is now -328.26% below its all-time high of -$3.62 million, reached on March 31, 2003.
Performance
CYCC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CYCC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.0% | +59.3% | +39.0% |
| 3 y3 years | -139.5% | +70.2% | +45.3% |
| 5 y5 years | -167.1% | +70.2% | +45.3% |
CYCC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -13.8% | +8.0% | at high | +75.4% | at high | +46.3% |
| 5 y | 5-year | -163.1% | +8.0% | at high | +75.4% | -60.6% | +46.3% |
| alltime | all time | -103.2% | +36.4% | -3.4% | +83.3% | -328.3% | +63.8% |
Cyclacel Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.18 M(-40.2%) | -$15.52 M(-23.1%) |
| Jun 2024 | - | -$3.64 M(-16.4%) | -$20.18 M(-10.2%) |
| Mar 2024 | - | -$4.35 M(-18.7%) | -$22.46 M(-11.6%) |
| Dec 2023 | -$25.42 M(-8.0%) | -$5.35 M(-21.7%) | -$25.42 M(-12.1%) |
| Sep 2023 | - | -$6.84 M(+15.5%) | -$28.91 M(+1.3%) |
| Jun 2023 | - | -$5.92 M(-19.0%) | -$28.53 M(+0.5%) |
| Mar 2023 | - | -$7.31 M(-17.3%) | -$28.39 M(+2.8%) |
| Dec 2022 | -$27.62 M(+23.6%) | -$8.84 M(+36.8%) | -$27.62 M(+11.5%) |
| Sep 2022 | - | -$6.46 M(+11.8%) | -$24.77 M(+1.9%) |
| Jun 2022 | - | -$5.78 M(-11.8%) | -$24.29 M(-1.2%) |
| Mar 2022 | - | -$6.55 M(+9.6%) | -$24.60 M(+10.1%) |
| Dec 2021 | -$22.35 M(+110.5%) | -$5.98 M(-0.2%) | -$22.34 M(+14.4%) |
| Sep 2021 | - | -$5.99 M(-1.6%) | -$19.53 M(+21.2%) |
| Jun 2021 | - | -$6.08 M(+41.6%) | -$16.11 M(+28.9%) |
| Mar 2021 | - | -$4.30 M(+35.8%) | -$12.49 M(+17.7%) |
| Dec 2020 | -$10.62 M(+9.9%) | -$3.16 M(+23.3%) | -$10.62 M(+3.7%) |
| Sep 2020 | - | -$2.57 M(+4.0%) | -$10.24 M(+2.2%) |
| Jun 2020 | - | -$2.47 M(+2.0%) | -$10.02 M(+1.4%) |
| Mar 2020 | - | -$2.42 M(-13.3%) | -$9.88 M(+2.3%) |
| Dec 2019 | -$9.66 M(+1.5%) | -$2.79 M(+19.0%) | -$9.66 M(+3.5%) |
| Sep 2019 | - | -$2.34 M(+0.4%) | -$9.33 M(-1.1%) |
| Jun 2019 | - | -$2.33 M(+6.1%) | -$9.44 M(-1.3%) |
| Mar 2019 | - | -$2.20 M(-10.6%) | -$9.56 M(+0.5%) |
| Dec 2018 | -$9.52 M(+0.6%) | -$2.46 M(+0.4%) | -$9.52 M(+2.9%) |
| Sep 2018 | - | -$2.45 M(-0.4%) | -$9.25 M(+3.9%) |
| Jun 2018 | - | -$2.46 M(+14.0%) | -$8.91 M(-0.3%) |
| Mar 2018 | - | -$2.15 M(-1.6%) | -$8.93 M(-5.6%) |
| Dec 2017 | -$9.46 M(-32.5%) | -$2.19 M(+4.1%) | -$9.46 M(-9.2%) |
| Sep 2017 | - | -$2.10 M(-15.2%) | -$10.41 M(-11.4%) |
| Jun 2017 | - | -$2.48 M(-7.6%) | -$11.75 M(-9.6%) |
| Mar 2017 | - | -$2.68 M(-14.7%) | -$13.00 M(-7.3%) |
| Dec 2016 | -$14.02 M(-12.2%) | -$3.15 M(-8.7%) | -$14.02 M(-4.5%) |
| Sep 2016 | - | -$3.44 M(-7.6%) | -$14.68 M(+0.7%) |
| Jun 2016 | - | -$3.73 M(+0.7%) | -$14.58 M(+1.1%) |
| Mar 2016 | - | -$3.70 M(-2.8%) | -$14.42 M(-9.7%) |
| Dec 2015 | -$15.96 M(-28.3%) | -$3.81 M(+14.0%) | -$15.96 M(-10.7%) |
| Sep 2015 | - | -$3.34 M(-6.4%) | -$17.88 M(-11.2%) |
| Jun 2015 | - | -$3.57 M(-32.0%) | -$20.14 M(-9.0%) |
| Mar 2015 | - | -$5.25 M(-8.3%) | -$22.12 M(-0.6%) |
| Dec 2014 | -$22.26 M(+24.3%) | -$5.72 M(+2.2%) | -$22.26 M(+8.6%) |
| Sep 2014 | - | -$5.60 M(+0.9%) | -$20.50 M(-0.8%) |
| Jun 2014 | - | -$5.55 M(+3.1%) | -$20.67 M(+7.3%) |
| Mar 2014 | - | -$5.39 M(+36.0%) | -$19.27 M(+12.0%) |
| Dec 2013 | -$17.90 M | -$3.96 M(-31.4%) | -$17.21 M(-6.0%) |
| Sep 2013 | - | -$5.77 M(+39.3%) | -$18.30 M(+13.8%) |
| Jun 2013 | - | -$4.14 M(+24.4%) | -$16.08 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$3.33 M(-34.1%) | -$15.43 M(+1.5%) |
| Dec 2012 | -$15.05 M(-0.8%) | -$5.05 M(+42.0%) | -$15.20 M(+10.2%) |
| Sep 2012 | - | -$3.56 M(+1.9%) | -$13.79 M(+1.7%) |
| Jun 2012 | - | -$3.49 M(+12.6%) | -$13.56 M(-0.7%) |
| Mar 2012 | - | -$3.10 M(-14.9%) | -$13.66 M(-10.4%) |
| Dec 2011 | -$15.17 M(-2.2%) | -$3.64 M(+9.6%) | -$15.25 M(+10.5%) |
| Sep 2011 | - | -$3.33 M(-7.4%) | -$13.80 M(-3.5%) |
| Jun 2011 | - | -$3.59 M(-23.5%) | -$14.31 M(-3.0%) |
| Mar 2011 | - | -$4.69 M(+114.4%) | -$14.76 M(-2.6%) |
| Dec 2010 | -$15.50 M(-21.2%) | -$2.19 M(-42.9%) | -$15.15 M(-12.2%) |
| Sep 2010 | - | -$3.83 M(-5.2%) | -$17.27 M(+3.3%) |
| Jun 2010 | - | -$4.04 M(-20.6%) | -$16.72 M(-14.4%) |
| Mar 2010 | - | -$5.09 M(+18.4%) | -$19.53 M(-0.2%) |
| Dec 2009 | -$19.67 M(-50.8%) | -$4.30 M(+30.8%) | -$19.56 M(-13.0%) |
| Sep 2009 | - | -$3.29 M(-52.0%) | -$22.48 M(-30.3%) |
| Jun 2009 | - | -$6.85 M(+33.5%) | -$32.25 M(-8.3%) |
| Mar 2009 | - | -$5.13 M(-28.9%) | -$35.15 M(-11.5%) |
| Dec 2008 | -$39.95 M(+30.2%) | -$7.21 M(-44.8%) | -$39.71 M(-7.3%) |
| Sep 2008 | - | -$13.06 M(+34.0%) | -$42.83 M(+17.1%) |
| Jun 2008 | - | -$9.75 M(+0.7%) | -$36.57 M(+10.3%) |
| Mar 2008 | - | -$9.68 M(-6.3%) | -$33.16 M(+11.2%) |
| Dec 2007 | -$30.68 M(-4.2%) | -$10.34 M(+52.0%) | -$29.82 M(+14.7%) |
| Sep 2007 | - | -$6.80 M(+7.1%) | -$26.00 M(+2.2%) |
| Jun 2007 | - | -$6.35 M(+0.2%) | -$25.44 M(-5.4%) |
| Mar 2007 | - | -$6.34 M(-2.8%) | -$26.88 M(-16.1%) |
| Dec 2006 | -$32.04 M(+64.7%) | -$6.52 M(+4.5%) | -$32.04 M(+4.9%) |
| Sep 2006 | - | -$6.24 M(-20.0%) | -$30.55 M(+10.1%) |
| Jun 2006 | - | -$7.79 M(-32.2%) | -$27.75 M(+9.9%) |
| Mar 2006 | - | -$11.49 M(+128.7%) | -$25.24 M(+29.8%) |
| Dec 2005 | -$19.45 M(-22.8%) | -$5.03 M(+46.0%) | -$19.45 M(-11.4%) |
| Sep 2005 | - | -$3.44 M(-34.8%) | -$21.96 M(-12.3%) |
| Jun 2005 | - | -$5.28 M(-7.4%) | -$25.04 M(-1.8%) |
| Mar 2005 | - | -$5.70 M(-24.3%) | -$25.50 M(+1.2%) |
| Dec 2004 | -$25.21 M(+49.1%) | -$7.54 M(+15.7%) | -$25.21 M(+13.9%) |
| Sep 2004 | - | -$6.51 M(+13.3%) | -$22.13 M(+14.4%) |
| Jun 2004 | - | -$5.75 M(+6.4%) | -$19.34 M(+3.5%) |
| Mar 2004 | - | -$5.41 M(+21.1%) | -$18.69 M(+10.5%) |
| Dec 2003 | -$16.91 M(-13.9%) | -$4.46 M(+19.8%) | -$16.91 M(+35.9%) |
| Sep 2003 | - | -$3.72 M(-26.9%) | -$12.45 M(+42.7%) |
| Jun 2003 | - | -$5.10 M(+40.6%) | -$8.72 M(+140.6%) |
| Mar 2003 | - | -$3.62 M | -$3.62 M |
| Dec 2002 | -$19.64 M(-1.2%) | - | - |
| Dec 2001 | -$19.88 M(+46.5%) | - | - |
| Dec 2000 | -$13.56 M(-101.7%) | - | - |
| Jan 1994 | $788.80 M(+13.3%) | - | - |
| Jan 1993 | $696.50 M | - | - |
FAQ
- What is Cyclacel Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual EBITDA year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Cyclacel Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals TTM EBITDA year-on-year change?
What is Cyclacel Pharmaceuticals annual EBITDA?
The current annual EBITDA of CYCC is -$25.42 M
What is the all time high annual EBITDA for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual EBITDA is $788.80 M
What is Cyclacel Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CYCC annual EBITDA has changed by +$2.20 M (+7.97%)
What is Cyclacel Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of CYCC is -$2.18 M
What is the all time high quarterly EBITDA for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly EBITDA is -$2.10 M
What is Cyclacel Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CYCC quarterly EBITDA has changed by +$3.18 M (+59.34%)
What is Cyclacel Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of CYCC is -$15.52 M
What is the all time high TTM EBITDA for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high TTM EBITDA is -$3.62 M
What is Cyclacel Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CYCC TTM EBITDA has changed by +$9.90 M (+38.95%)